IDXX Stock Recent News

IDEXX's robust strength in the CAG Diagnostics business and strong global performance are highly promising.

WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in two upcoming conferences: Thursday, February 27, 9:05 am – 9:45 am EST – Mike Erickson, PhD, Executive Vice President, and General Manager, Point of Care Diagnostics and Telemedicine, and Andrew Emerson, Senior Vice President, Corporate and CAG Finance, will participate in a fireside chat at the virtual BofA Securities Animal Health Summit. Monday, March.

IDEXX Laboratories stock has shown consistent long-term annualized growth of 24.75%. Despite a tough year with a 20% loss, IDEXX remains strong, fundamentally. IDEXX's innovative products and international growth offset declining US clinical visits, projecting an 11.54% annual EPS growth over the next five years.

Shares of leading pet healthcare diagnostics provider Idexx Laboratories (IDXX -1.70%) were up by 9% this week as of 4 p.m. ET Thursday, according to data provided by S&P Global Market Intelligence.

IDEXX Laboratories is poised for growth in the pet healthcare market, driven by an aging pet population and strong pet-owner bonds. IDEXX's comprehensive ecosystem, including AI-driven diagnostics and software, enhances veterinary practices and pet health monitoring, creating significant value for pet owners. IDEXX's strong balance sheet, shareholder-friendly capital allocation, and high ROIC of 32% indicate robust financial health and competitive advantage.

Idexx Laboratories, AbbVie, and Molina Healthcare trade higher on a down day for Wall Street.

IDEXX Laboratories, Inc. (NASDAQ:IDXX ) Q4 2024 Earnings Conference Call February 3, 2025 8:30 AM ET Company Participants Brian McKeon - Chief Financial Officer Andrew Emerson - Senior Vice President, Corporate & Companion Animal Group Finance Jay Mazelsky - President & Chief Executive Officer Conference Call Participants Erin Wright - Morgan Stanley Chris Schott - JPMorgan Michael Ryskin - Bank of America Jon Block - Stifel Daniel Clark - Leerink Partners Navann Ty - BNP Paribas Exane Operator Good morning, and welcome to the IDEXX Laboratories' Fourth Quarter 2024 Earnings Conference Call. As a reminder, today's conference is being recorded.

Shares of IDEXX Laboratories (IDXX) surged 10% to lead S&P 500 gainers Monday after the provider of veterinary healthcare products and services reported better-than-anticipated results on demand for its animal testing products and higher prices.

Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Veterinary diagnostics specialist Idexx Laboratories (IDXX -0.46%) reported fourth-quarter earnings on Monday, Feb. 3, that topped analysts' consensus top- and bottom-line estimates. Revenue for the quarter came in at $954 million against the expected $935 million.